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Abstract
Background: Procalcitonin (PCT) is increasingly being 
used for the diagnostic and prognostic work up of patients 
with suspected infections in the emergency department 
(ED). Recently, B·R·A·H·M·S PCT direct, the first high sen-
sitive point-of-care test (POCT), has been developed for fast 
PCT measurement on capillary or venous blood samples.
Methods: This is a prospective, international compari-
son study conducted in three European EDs. Consecu-
tive patients with suspicion of bacterial infection were 
included. Duplicate determination of PCT was performed 
in capillary (fingertip) and venous whole blood (EDTA), 
and compared to the reference method. The diagnostic 
accuracy was evaluated by correlation and concordance 
analyses.
Results: Three hundred and three patients were included 
over a 6-month period (60.4% male, median age 65.2 
years). The correlation between capillary or venous whole 
blood and the reference method was excellent: r2 = 0.96 
and 0.97, sensitivity 88.1% and 93.0%, specificity 96.5% 
and 96.8%, concordance 93% and 95%, respectively at 
a 0.25 μg/L threshold. No significant bias was observed 
(–0.04 and –0.02 for capillary and venous whole blood) 
although there were 6.8% and 5.1% outliers, respectively. 
B·R·A·H·M·S PCT direct had a shorter time to result as 
compared to the reference method (25 vs. 144 min, differ-
ence 119 min, 95% CI 110–134 min, p < 0.0001).
Conclusions: This study found a high diagnostic accuracy 
and a faster time to result of B·R·A·H·M·S PCT direct in 
the ED setting, allowing shortening time to therapy and a 
more wide-spread use of PCT.
Keywords: antibiotic therapy; emergency department; 
infection; method comparison; point-of-care testing; 
procalcitonin.
Introduction
Delays in diagnosis of bacterial infections and sepsis are 
the single most effective modifiable factor associated with 
poor sepsis outcome [1–4]. Rapid rule out and/or confir-
mation of sepsis is, therefore, an essential element in the 
initial work up of patients with suspicion of infection in 
the emergency department (ED). For this purpose, point-
of-care testing (POCT) with a short time between sample 
acquisition and analysis of infection blood markers pro-
vides new opportunities. Effective use of POCT technology 
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in the ED has great potential to decrease delays in initia-
tion of antimicrobial treatment and increase ED efficiency, 
by alleviating negative effects of overcrowding EDs [5]. 
POCT is performed directly at the patient bedside with 
minimal time delays due to absent preanalytics and trans-
portation of samples to the central laboratory.
Procalcitonin (PCT), a biomarker of bacterial infec-
tions, is increasingly being used for early risk stratifica-
tion of patients with suspected sepsis and for antibiotic 
stewardship [6, 7]. Due to higher specificity compared to 
more traditional markers, PCT helps in the differentia-
tion of bacterial and viral infections [8]. In addition, a 
meta-analysis found an overall sensitivity of 77% and a 
 specificity of 79% of PCT to distinguish between sepsis and 
systemic inflammatory response syndrome (SIRS) of non-
infectious origin in critically ill patients [9]. In addition, 
several interventional trials found a marked reduction in 
overall antibiotic use and duration of antibiotic courses in 
patients with respiratory infections when PCT was used as 
a stewardship guide without compromising outcome [10–
12]. Two of these trials were done in primary care practices 
where PCT was not measured on site but sent to a refer-
ence lab [13, 14]. A major limitation of current PCT testing 
is the lack of sensitive POCT which may help to have test 
results earlier and in smaller facilities without reference 
laboratories (i.e. smaller EDs, outpatient clinics).
A novel quantitative immunochromatographic whole 
blood POCT was developed. In accordance with CLSI (Clin-
ical and Laboratory Standards Institute) guideline EP5-A 
the inter assay precision is  < 20% coefficient of variation 
(CV) at a 0.5 μg/L level;  < 15% at a ~2 μg/L level;  < 20% 
at a ~8 μg/L level and the functional assay sensitivity 
is  < 0.25 μg/L. Herein, we prospectively compared the 
performance between this new POCT and the reference 
method (B·R·A·H·M·S PCT sensitive Kryptor or Elecsys 
B·R·A·H·M·S PCT) in the ED routine terms in patients with 
suspicion of bacterial infection.
Materials and methods
Patients, setting, ethics
This is a prospective, comparative international multicenter study 
including ED patients with suspicion of bacterial infection undergo-
ing routine care PCT measurement. Adult patients (age ≥ 18 years) 
from three hospitals in Germany, France, and Switzerland were 
included between April 2013 and April 2014. Patients had to have 
a possible bacterial infection at initial presentation based on the 
assessment of the treating ED physicians, and be willing to give writ-
ten informed consent. The exclusion criteria were non-adult patients 
( < 18 years of age), pregnant or breastfeeding women, and persons 
incapable of acting in law. Data on demographics, diagnosis, labora-
tory parameters and site-of-care decision were assembled for each 
patient upon admission and during hospital stay.
The approval for this study was obtained from all Local Ethical 
Committees and all patients gave written informed consent. The study 
was registered in the “ClinicalTrials.gov” Database (http://www.clin-
icaltrials.gov/ct2/show/NCT01771029, identifier NCT01771029).
Objectives and evaluation plan
The primary objective of this study is to show an at least 90% cor-
relation between B·R·A·H·M·S PCT direct™ and the PCT reference 
method within the measuring range of B·R·A·H·M·S PCT direct (0.1–
10.0 μg/L) and a concordance for normal range and increased PCT 
concentrations at the clinical cut-off of 0.25 μg/L and 0.5 μg/L PCT. 
Previously, an excellent correlation and concordance was described 
comparing the two involved reference methods (B·R·A·H·M·S PCT 
sensitive™ Kryptor™ or Elecsys® B·R·A·H·M·S PCT™) [15], meaning 
there was no measuring discrepancy between the reference methods. 
The secondary objective of this study is to compare time to result of 
the B·R·A·H·M·S PCT direct with the reference methods.
To perform the method comparison, one ethylenediaminetet-
raacetic acid (EDTA) blood sample and two fingertip blood samples 
were collected from each included patient at the same time point. 
For duplicate determination of all blood samples two distinct readers 
were used.
Blood taking
Because of the limited stability of the used specimen type (whole 
blood) a retrospective freezer evaluation with native patient samples 
was not possible. The prospective evaluation was designed with a 
minimum additional intervention for each patient. For the evalua-
tion, 20 μL capillary blood of fingertip and one tube (approximately 
5 mL) EDTA whole blood (taken from the routine blood withdrawal) 
from each enrolled patient was needed. The EDTA whole blood/
plasma was used for the method comparison and for the technical 
evaluation. Results of B·R·A·H·M·S PCT direct did not influence any 
clinical decision and were noted in a blinded form. The blood samples 
were used for immediate measurement of the B·R·A·H·M·S PCT direct 
assay (20  min measuring time). Subsequently, the remaining sam-
ple volume of EDTA blood was centrifuged and the resulting plasma 
analysed by a PCT reference method. As a reference method, in 
France and Switzerland the Kryptor (ThermoFisher) device was used, 
whereas in Germany the Elecsys (Roche) system was available. The 
remaining plasma was deep-frozen at –20 °C for later analysis of all 
samples evaluating concordance to further PCT reference methods.
Sample size calculation
Overall test accuracy was calculated as the proportion of subject 
samples categorised correctly by B·R·A·H·M·S PCT direct test vs. the 
reference method (sum of true positives and true negatives divided 
by the total number of samples). Assuming that the concordance 
between the two assays is at least 93%, a total of 171 unique subject 
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samples will provide an estimate that is within ±3% of the true value 
with 90% confidence. If the concordance is at least 95%, 80 samples 
are sufficient to provide an estimate ±5% of the true value with 95% 
confidence. Due to the supposed high variability in clinical real-life 
conditions we aimed to collect at least 200 unique subject samples in 
order to be able to demonstrate that the concordance is larger than 
90%.
Statistics
Discrete variables are expressed as counts (percentage) and con-
tinuous variables are expressed as medians and interquartile ranges 
(IQR: 25th–75th percentiles) unless stated otherwise. Duplicate 
B·R·A·H·M·S PCT direct values were averaged and the mean was 
taken for further analysis. All testing was two-tailed and p < 0.05 
were considered to indicate statistical significance. Comparison of 
B·R·A·H·M·S PCT direct and the reference method was evaluated by 
the Passing and Bablok regression analysis and a Bland-Altman dif-
ference plot. In the latter, the mean PCT levels of both methods are 
plotted on the x-axis and the mean difference, as an absolute devia-
tion, on the y-axis. Clinical concordance between B·R·A·H·M·S PCT 
direct and the reference method over two clinically relevant PCT 
cut-offs (0.25 μg/L and 0.5 μg/L) was assessed by calculating the к 
coefficient. Analyses were performed with STATA 12.1 (Stata Corp., 
College Station, TX, USA) and Analyse-it for Microsoft Excel.
Results
Patient population and baseline 
characteristics
A total of 303 ED patients (60.4% male, median age 
65.2 years) were included for this comparison study. From 
these, 36 capillary and six venous measurements were 
missing due to handling errors (Figure 1A). From the remain-
ing 267 B·R·A·H·M·S PCT direct capillary samples, 151 
(56.6%) samples had a PCT value of 0.25 μg/L or below. In 
B·R·A·H·M·S PCT direct venous samples 159 of 297 patients 
(53.5%) showed a PCT value of 0.25 μg/L (clinically relevant 
for decision to initiate/discontinue antibiotic therapy) or 
316 patients with
suspected bacterial
infection
303 samples from
patients protocol
8 insufficient blood sampling
1 refused participation
3 missing informed consent
1 inconsistant raw data
267 capillary blood
samples
297 venous blood
samples
6 missing venous measurement
36 missing capillary
measurement, handling errors 
Patients, n
A
B
PCT 
<0.1 µg/L
PCT 0.1- PCT >0.25- PCT >0.5- 
<10.0µg/L
PCT 
B·R·A·H·M·S
PCT direct
capillary
267 56 95 31 76 9
B·R·A·H·M·S
PCT direct
venous
297 66 93 33 93 12
Reference
303 81 79 42 83 18
10.0 µg/L0.5 µg/L0.25 µg/L
Figure 1: (A) Flow diagram of patient enrolment; (B) PCT level distribution according to the measuring range.
PCT, procalcitonin.
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below. 202 (75.7%) B·R·A·H·M·S PCT direct capillary and 219 
(73.7%) B·R·A·H·M·S PCT direct venous measurements were 
within the measuring range (Figure 1B).
Baseline characteristics of the overall cohort and sep-
arated by clinical centre are depicted in Table 1. Overall, 
183 blood cultures were taken, whereof 30 (16.4%) were 
positive. A total of 162 (53.5%) patients had a final ED 
diagnosis of a bacterial infection and 243 (80.2%) patients 
were finally admitted to the hospital at which 23 (7.6%) 
patients had to be transferred to the intensive care unit 
(ICU) over the course of hospital stay.
Comparison B·R·A·H·M·S PCT direct vs. 
reference method
Comparison of B·R·A·H·M·S PCT direct (values within 
the measuring range [0.1–10.0 μg/L]) with the reference 
method was performed in all cases with PCT measure-
ments available from both methods. Regression analysis 
of B·R·A·H·M·S PCT direct capillary (n = 202) and venous 
(n = 219) samples and the reference method showed a very 
high correlation (r2 = 0.97, slope: 0.90 [95% CI: 0.86–0.96], 
intercept: 0.03 [95% CI: 0.02–0.04] and r2 = 0.95, slope: 0.98 
[95% CI: 0.93–1.02], intercept: 0.02 [95% CI: 0.01–0.03], 
respectively; Figure 2A and B). Accordingly, the correlation 
between capillary and venous samples on B·R·A·H·M·S 
PCT direct (n = 194) – excluding samples with PCT outside 
the detection range – showed the following parameters: 
r2 = 0.98, slope: 1.01 [95% CI: 1.00–1.05], intercept: –0.00 
[95% CI: 0.01–0.00] (Figure 2C). Based on this regression 
analysis, the clinically most relevant decision points (e.g. 
0.25 μg/L and 0.5 μg/L) on the B·R·A·H·M·S PCT direct 
were not altered (data not shown).
The concordance between B·R·A·H·M·S PCT direct and 
the reference method at a clinically relevant PCT cut-off 
(0.25 μg/L) was 92.5% for capillary and 94.9% for venous 
samples. A PCT cut-off at 0.5 μg/L also revealed high per-
centages of agreement for capillary (96.3%) and venous 
samples (96.6%). As illustrated in Table  2, B·R·A·H·M·S 
PCT direct showed a very high sensitivity at a 0.25 μg/L 
cut-off in both capillary (88.9% [95% CI: 0.82–0.94]) and 
venous samples (93.7% [95% CI: 0.88–0.97]).
Even more sensitive were the results considering 
the 0.5 μg/L cut-off, 94.2% (95% CI: 0.87–0.98) in capil-
lary and 98.0% (95% CI: 0.93–1.00) in venous measure-
ments. The specificity ranged between 95.9% and 97.2% 
in all categories. Concordance levels ranged between 93% 
in capillary samples at the 0.25 μg/L cut-off and 97% in 
venous samples at the 0.5 μg/L cut-off.
For capillary and venous B·R·A·H·M·S PCT direct 
measurements the mean difference (95% limits of agree-
ment) to the reference method was –0.05 (–1.226 to 1.126) 
and 0.023 (–1.014 to 1.060), respectively (Figure  3). Any 
bias could not be detected, however we identified some 
outlying PCT values, mainly in the high-value category.
Time to result B·R·A·H·M·S PCT direct vs. 
reference method
As shown in Figure 4, the overall time to result could be 
significantly reduced by using the B·R·A·H·M·S PCT direct 
assay. Overall, we found a mean time reduction of 119 min 
between the POCT and the reference methods namely 
from 2 h 24 min to 25 min (p = 0.0001).
Discussion
This is the first study comparing the new B·R·A·H·M·S PCT 
direct assay with a laboratory based automated reference 
Table 1: Baseline characteristics.
Parameter   All (n = 303)  Germany (n = 53)  France (n = 118)  Switzerland (n = 132)  p-Value
Demographics          
 Age, years; median (IQR)   67.9 (54.6–79.3)  69.8 (60.1–78.0)  64.6 (46.8–84.2)  69.0 (57.7–78.2)  0.5070
 Men, n (%)   184 (60.7)  30 (56.6)  72 (61.0)  82 (62.1)  0.7835
 Diagnostics, n (%)          
 Blood culture collected   183 (60.4)  30 (56.6)  50 (42.4)  103 (78.0)  0.0001
 Positive blood cultures   30 (16.4)  5 (16.7)  3 (6.0)  22 (21.4)  0.6321
Primary diagnosis          
 Bacterial infection   162 (53.5)  39 (73.6)  39 (33.1)  84 (63.6)  0.0001
 Hospital admission, n (%)   243 (80.2)  46 (86.8)  71 (60.2)  126 (95.5)  0.0001
 ICU admission, n (%)   23 (7.6)  7 (13.2)  12 (10.2)  4 (3.0)  0.5408
 PCT auto μg/L; median (IQR)  0.21 (0.09–0.87)  0.13 (0.08–0.70)  0.13 (0.07–0.36)  0.44 (0.14–1.72)  0.0001
PCT, procalcitonin; ICU, intensive care unit; IQR, interquartile range; auto, automated (reference method).
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Figure 2: Correlation of averaged duplicate B·R·A·H·M·S PCT direct values and reference method.
(A) Capillary vs. reference method; (B) venous vs. reference method; (C) capillary vs. venous; PCT, procalcitonin; blue lines indicating 0.25 
and 0.5 μg/L cut-offs, respectively.
Table 2: Diagnostic accuracy of B·R·A·H·M·S PCT direct at clinically relevant PCT cut-offs.
Cut-off, μg/L  
 
0.25 μg/L 
 
0.5 μg/L
Sens., % 
(95% CI)
  Spec., % 
(95% CI)
  Concordance, 
%
Sens., % 
(95% CI)
  Spec., % 
(95% CI)
  Concordance, 
%
B·R·A·H·M·S PCT direct capillary           
 n = 267   88.9
(0.82–0.94)
  96.5
(0.92–0.99)
  92.5  94.2
(0.87–0.98)
  97.2
(0.94–0.99)
  96.3
B·R·A·H·M·S PCT direct venous            
 n = 297   93.7
(0.88–0.97)
  96.8
(0.93–0.99)
  94.9  98.0
(0.93–1.00)
  95.9
(0.92–0.98)
  96.6
PCT, procalcitonin; Sens., sensitivity; Spec., specificity; CI, confidence interval.
method (Kryptor or Elecsys) for measurement of PCT in 
the ED setting. As a primary result, a high correlation was 
found without a clinically significant bias. In addition, 
time to result was markedly reduced compared to the ref-
erence method measurement.
In the last decade, other quantitative automated 
options for PCT testing have been described, including the 
Liaison BRAHMS PCT (DiaSorin) [16], Elecsys BRAHMS 
PCT (Roche Diagnostics) [15], Advia Centaur BRAHMS PCT 
(Siemens) [17] and VIDAS (bioMérieux) [18] with good cor-
relation but missing important characteristics of a POCT 
application.
Recently, a new, highly sensitive fluorescence immune 
assay for a TIRF (total internal reflection)-based POCT 
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Figure 4: Time to result: B·R·A·H·M·S PCT direct vs. reference 
method.
p < 0.0001.
device was developed for the detection of PCT [19]. They 
tested for the first time a diagnostic device for sepsis to 
use whole blood, which is a crucial requirement for POCT 
and were able to detect native PCT in patient samples with 
a good correlation compared to the Kryptor. Similar to 
the above mentioned POCT, the B·R·A·H·M·S PCT direct 
fulfills all the essential characteristics of a POCT includ-
ing a small – and easy to handle-sample volume (20 μL), 
a high sensitivity, a clinically relevant measuring range 
(0.1–10.0 μg/L) and a fast time to result.
In contrast to the others studies, we also performed 
real-life time to result ascertainments from the bedside 
blood collection to the print-out of the measurement. A 
further strength is the prospective multicenter character 
of this study conducted under clinical routine conditions 
in different countries and health care systems. These char-
acteristics are important for underlining the suitability for 
daily use in the EDs with low variability.
In clinical routine, PCT cut-off ranges are often used 
to guide initiation and duration of antimicrobial treat-
ment [20, 21]. In this context, our findings showing a high 
correlation of the new POCT with the reference methods 
across cut-off ranges are reassuring. First, the Bland-
Altman plot did not show any relevant bias comparing 
capillary and venous B·R·A·H·M·S PCT direct measure-
ments as well as B·R·A·H·M·S PCT direct and reference 
method measurements. Because we did not re-perform a 
concordance analysis between the two involved reference 
methods and accepted – based on a previous publication 
[15] – the pre-calculated concordance, a certain imprecise-
ness cannot be completely excluded. Secondly, the data 
from three tertiary care hospitals in Europe show a high 
concordance ( ≥ 93%) over both relevant critical decision 
PCT cut-offs (0.25 μg/L and 0.5 μg/L) without a significant 
change in frequency distribution. Given the limitation that 
we did not perform a state-of-the-art precision calculation, 
we assume – based on these findings – B·R·A·H·M·S PCT 
direct PCT measurements would lead to the same decision 
for or against initiating antibiotic therapy as compared 
to the reference method. Furthermore, B·R·A·H·M·S PCT 
direct could serve as a solid basis to develop more POCT 
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systems in the future involving other biomarkers. In this 
case, an indispensable condition is to directly link the 
POCT system to the clinic software, to avoid manual data 
input. If implemented, POCT may increase ED effective-
ness and thereby helps to lessen the burden of overcrowd-
ing, decrease time to antibiotic therapy and improve 
risk stratification without delaying patient management 
decisions. Until now, available POCT systems involving 
other sepsis biomarker (e.g. lactate) were associated with 
reduced turnaround times, without investigating medical 
outcome [22], however a separate study found improved 
outcomes in patients with higher lactate clearance com-
pared with patients with lower clearance [23]. This rela-
tionship between time-to-treatment initiation and patient 
outcome highlights the need for expedited diagnosis 
through POCT. This study is obviously unable to proof this 
hypothesis, however, future evaluations should address 
this important aspect of POCT as already stated by a recent 
review asking about evidence of using POCT [24].
PCT protocols have been used mainly for manage-
ment of in-hospital and intensive care patients mainly 
because of the more wide-spread availability of assays 
in these settings. Arguably, the most important antibio-
tic overuse occurs in the outpatient/general practitioner 
(GP) setting. Previous randomized trials have found 
important reductions in antibiotic use in outpatients 
associated with the use of PCT testing [13, 14]. As a major 
limitation, in these studies samples were sent to a core 
laboratory due to the lack of smaller PCT testing devices. 
The new high sensitive POCT technology may also open 
the door for a more wide spread use of PCT in the setting 
of outpatients and GPs.
Conclusions
B·R·A·H·M·S PCT direct, a new, sensitive POCT assay for 
PCT quantification was developed. The device conforms 
to all the important characteristics of a POCT application, 
such as a small sample volume, a high sensitivity, and a 
fast time to result under the routine terms. Samples must 
not be pretreated because the device uses ready-to-use 
cartridges. Furthermore, it is safe and simple to handle. To 
our best knowledge, this is the first time that a measure-
ment system for quantifying PCT under the terms of daily 
clinical emergency practice was developed that can be 
applied in whole blood samples.
The PCT assay on the B·R·A·H·M·S PCT direct shows 
an excellent correlation and concordance with the estab-
lished reference method. Additionally, the data support 
the use of the same nominal PCT cut-offs previously estab-
lished for this application. This is highly relevant for the 
routine implementation of PCT as a biomarker for anti-
biotic decision making in the ED setting. Due to a missing 
state-of-the-art precision analysis results must be inter-
preted in the clinical context of the patient.
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